var data={"title":"Metformin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metformin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6545?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">see &quot;Metformin: Drug information&quot;</a> and <a href=\"topic.htm?path=metformin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metformin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709034\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (&gt;5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and increased lactate/pyruvate ratio; and metformin plasma levels generally &gt;5 mcg/mL.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), &ge;65 years, having a radiological study with contrast, surgery and other procedures, hypoxic states (eg, acute congestive heart failure), excessive alcohol intake, and hepatic impairment.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If metformin-associated lactic acidosis is suspected, immediately discontinue metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193858\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>D-Care DM2;</li>\n      <li>Fortamet;</li>\n      <li>Glucophage;</li>\n      <li>Glucophage XR;</li>\n      <li>Glumetza;</li>\n      <li>Riomet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193859\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Glucophage;</li>\n      <li>Glumetza;</li>\n      <li>Glycon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060245\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidiabetic Agent, Biguanide</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidiabetic Agent, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hypoglycemic Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060238\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">see &quot;Metformin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2; treatment: Note:</b> Allow 1 to 2 weeks between dose titrations. Generally, clinically significant responses are not seen at doses less than 1,500 mg/day to 2,000 mg/day (AAP [Copeland 2013]); however, a lower recommended starting dose with a gradual increase in dosage is recommended to minimize gastrointestinal symptoms. Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release tablet or solution:  </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\"> Manufacturer's labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents 10 to 16 years: Initial: 500 mg twice daily; increase dose  in increments of 500 mg at weekly intervals; maximum daily dose: 2,000 mg/<b>day</b>. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: &ge;17 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Twice daily regimen: Initial: 500 mg twice daily; increase daily dose in increments of 500 mg/day  in 2 divided doses at weekly intervals; may also titrate from 500 mg twice a day to 850 mg twice a day after 2 weeks; recommended maximum daily dose: 2,550 mg/<b>day</b>; if a dose &gt;2,000 mg daily is required, it may be better tolerated if given in 3 divided doses  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Once daily regimen: Initial: 850 mg once daily; increase daily dose in increments of 850 mg/day every other week;  maximum daily dose: 2,550 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Children and Adolescents 10 to &lt; 18 years:  Initial:  500 mg once daily for 7 days, then increase in 500 mg increments at 1- to 2-week intervals  to a target dose of 1,000 mg twice daily (AAP [Copeland 2013]; ISPAD [Zeitzler 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release tablets:</i> <b>Note:</b> If glycemic control is not achieved at maximum dose, may divide dose and administer twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 10 to 16 years: Limited data available: Initial: 500 mg once daily; dosage may be increased by 500 mg at 1- to 2-week intervals; maximum daily dose: 2,000 mg/<b>day</b> (AAP [Copeland 2013]; ISPAD [Zeitzler 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fortamet: Adolescents &ge;17 years: Initial: 500 to 1,000 mg once daily; dosage may be increased by 500 mg weekly; maximum daily dose: 2,500 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Glucophage XR: Adolescents &ge;17 years: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Glumetza:  Adolescents &ge;18 years: Initial: 1,000 mg once daily; dosage may be increased by 500 mg weekly; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Obesity: Severe, adjunct therapy with lifestyle interventions:</b> Limited data available; data has shown modest efficacy (BMI reduction ~3%); optimal treatment duration not established; most trials 6 to 12 months in duration with largest BMI change usually observed in the first 3 to 4 months of therapy; a daily multivitamin supplement may be considered with therapy (AHA [Kelly 2013]; Matson 2012; McDonagh 2014): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Dosing regimens variable: Children &ge;6 years and Adolescents:  Initial:  500 mg once <b>or</b> twice daily, titrate upward at weekly intervals by 500 mg/day increments to a target dose of 1,000 mg administered in the morning and 500 mg in the evening or 1000 mg twice daily (Kendall 2013; Yanovski 2011); several other trials have reported doses of 500 mg twice daily dosing (Matson 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Metformin XR: Adolescents: Initial:  500 mg once daily with dinner for 2 weeks; increase to 1,000 mg once daily for 2 weeks, and then 2,000 mg once daily; may slow titration if adverse gastrointestinal effects; treatment continued for 4 months (Glaser Pediatric Research Network [Wilson 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Management of type 2 diabetes mellitus: Note:</b> Allow 1 to 2 weeks between dose titrations: Generally, clinically significant responses are not seen at doses &lt;1,500 mg daily; however, a lower recommended starting dose and gradual increased dosage is recommended to minimize gastrointestinal symptoms. Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release tablet or solution:</i> Initial: 500 mg twice daily or 850 mg once daily; titrate in increments of 500 mg weekly or 850 mg every other week; may also titrate from 500 mg twice a day to 850 mg twice a day after 2 weeks.  If a dose &gt;2,000 mg daily is required, it may be better tolerated in 3 divided doses; maximum daily dose: 2,550 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release tablet:</i> <b>Note</b>: If glycemic control is not achieved at maximum dose, may divide dose and administer twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fortamet: Initial: 500 to 1,000 mg once daily; dosage may be increased by 500 mg weekly; maximum daily dose: 2,500 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Glucophage XR: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Glumetza: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transfer from other antidiabetic agents:</b> No transition period is generally necessary except when transferring from chlorpropamide. When transferring from chlorpropamide, care should be exercised during the first 2 weeks because of the prolonged retention of chlorpropamide in the body, leading to overlapping drug effects and possible hypoglycemia. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concomitant metformin and oral sulfonylurea therapy:</b> If patients have not responded to 4 weeks of the maximum dose of metformin monotherapy, consider a gradual addition of an oral sulfonylurea, even if prior primary or secondary failure to a sulfonylurea has occurred. Continue metformin at the maximum dose. If adequate response has not occurred following 1 to 3 months of metformin and sulfonylurea combination therapy, consider switching to insulin with or without metformin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Failed sulfonylurea therapy:</b> Patients with prior failure on glyburide may be treated by gradual addition of metformin. Initiate with glyburide 20 mg and metformin 500 mg daily. Metformin dosage may be increased by 500 mg/day at weekly intervals, up to a maximum metformin dose (dosage of glyburide maintained at 20 mg daily).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concomitant metformin and insulin therapy:</b> Initial: 500 mg metformin once daily, continue current insulin dose; may increase by metformin 500 mg after ~1 week and by 500 mg every week thereafter until adequate glycemic control is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum daily metformin dose: Immediate release and solution: 2,550 mg/<b>day</b>; Extended release: 2,000 to 2,500 mg/<b>day</b> (varies by product)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Decrease insulin dose 10% to 25% when FPG &lt;120 mg/dL; monitor and make further adjustments as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;10 years and Adolescents:  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine (S<sub>cr</sub>) &ge;1.5 mg/dL (males) or &ge;1.4 mg/dL (females): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Abnormal CrCl: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum creatinine (S<sub>cr</sub>) &ge;1.5 mg/dL (males) or &ge;1.4 mg/dL (females): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Abnormal CrCl: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: <b>Note:</b> The United Kingdom National Institute for Health and Clinical Excellence (NICE) Guidelines recommends prescribing metformin with caution in those patients who are at risk of sudden deterioration in renal function and at risk of an estimated glomerular filtration rate (eGFR) &lt;45 mL/minute/1.73 m<sup>2</sup> (National Collaborating Centre [NICE 2008]). Some evidence suggests that use of metformin is unsafe when eGFR &lt;30 ml/minute/1.73 m<sup>2</sup> (calculated using MDRD) (Shaw 2007). A review of the available data by members of the American Diabetes Association proposed the following recommendations based on eGFR (Lipska 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">eGFR &ge;60 mL/minute/1.73 m<sup>2</sup>: No contraindications, monitor renal function annually</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">eGFR &ge;45 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Continue use; monitor renal function every 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">eGFR &ge;30 to &lt;45 mL/minute/1.73 m<sup>2</sup>: In patients currently receiving metformin, use with caution, consider dosage reduction (eg, 50% reduction or 50% of maximal dose), monitor renal function every 3 months. Do not initiate therapy in patients with eGFR &lt;45 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>Children &ge;10 years, Adolescents, and Adults: Avoid metformin; liver disease is a risk factor for the development of lactic acidosis during metformin therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193832\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-Care DM2: Extended release tablet, as hydrochloride: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Riomet: 500 mg/5 mL (118 mL, 473 mL) [contains propylene glycol; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Riomet: 500 mg/5 mL (118 mL, 473 mL) [contains saccharin calcium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage: 500 mg, 850 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage: 1000 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 850 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortamet: 500 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage XR: 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glumetza: 500 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 750 mg, 1000 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193817\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25484130\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">see &quot;Metformin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Extended release tablets utilize differing release mechanisms: Glucophage XR uses dual hydrophilic polymer matrix systems, Fortamet uses single-composition osmotic technology, and Glumetza uses gastric retention technology.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060249\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\"> Administer with a meal (to decrease GI upset).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immediate release: Glucophage, Riomet: Administer in divided doses with meals </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extended release:  Fortamet, Glucophage XR, Glumetza: Administer with evening meal; swallow whole; do not cut, crush, or chew; Fortamet should also be administered with a full glass of water</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193853\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursion permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060248\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of type 2 diabetes mellitus (noninsulin-dependent, NIDDM) when hyperglycemia cannot be managed with diet and exercise alone (Immediate release [tablets, oral solution]: FDA approved in ages &ge;10 years and adults; extended release: Fortamet, Glucophage XR: FDA approved in ages &ge;17 years and adults; Glumetza: FDA approved in ages &ge;18 years and adults); has also been used for weight loss in pediatric patients with severe obesity and insulin resistance in conjunction with a comprehensive lifestyle weight management program.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> If not contraindicated and if tolerated, metformin is the preferred initial pharmacologic agent for type 2 diabetes management (ADA 2000; ADA 2014; AAP [Copeland 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193915\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetFORMIN may be confused with metroNIDAZOLE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage may be confused with Glucotrol, Glutofac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dianben [Spain] may be confused with Diovan brand name for valsartan [U.S., Canada, and multiple international markets]. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Glucon brand name for metformin [Malaysia, Singapore] is also the brand name for glucosamine [Singapore]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193913\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest discomfort, flushing, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, headache, taste disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, nail disease, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased vitamin B<sub>12</sub> serum concentrate, hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: abdominal distention, abdominal distress, abdominal pain, abnormal stools, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, flu-like symptoms, rhinitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hepatic injury (cholestatic, hepatocellular, and mixed), lactic acidosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193840\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity to metformin or any component of the formulation; severe renal dysfunction (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>); acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to metformin or any component of the formulation; renal function unknown, renal impairment, and serum creatinine levels above the upper limit of normal range; renal disease or renal dysfunction (serum creatinine &ge;136 micromol/L in males or &ge;124 micromol/L in females or abnormal creatinine clearance &lt;60 mL/minute) which may result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia; unstable and/or insulin-dependent (type I) diabetes mellitus; acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma; history of lactic acidosis (regardless of precipitating factors); excessive alcohol intake (acute or chronic); severe hepatic dysfunction or clinical or laboratory evidence of hepatic disease; cardiovascular collapse and disease states associated with hypoxemia including cardiorespiratory insufficiency, which are often associated with hyperlactacidemia; stress conditions (eg, severe infection, trauma, surgery and postoperative recovery phase); severe dehydration; pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193821\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis: <b>[US Boxed Warning]: </b><b>Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset is often subtle, accompanied by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain); elevated blood lactate levels (&gt;5 mmol/L); anion gap acidosis (without evidence of ketonuria or ketonemia); increased lactate:pyruvate ratio; metformin plasma levels generally &gt;5 mcg/mL. Risk factors for lactic acidosis include patients with renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), &ge;65 years, having a radiologic study with contrast, surgery and other procedures, hypoxic states (eg, acute heart failure), excessive alcohol intake, and hepatic impairment. Discontinue immediately if lactic acidosis is suspected; prompt hemodialysis is recommended.</b> Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue use in patients with conditions associated with dehydration, hypoperfusion, sepsis, or hypoxemia. Temporarily discontinue therapy in patients with restricted food and fluid intake. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> concentrations: Long-term metformin use is associated with vitamin B<sub>12</sub> deficiency; monitor vitamin B<sub>12</sub> serum concentrations periodically with long-term therapy. Monitoring of B<sub>12</sub> serum concentrations should be considered in all patients receiving metformin and in particular those with peripheral neuropathy or anemia (ADA 2018d).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Metformin may be used in patients with stable heart failure (HF); avoid use in unstable or hospitalized patients with heart failure (ADA 2018h). Risk of lactic acidosis may be increased secondary to hypoperfusion. In a scientific statement from the American Heart Association, metformin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]). Use of metformin in patients with HF may be associated with reduced mortality and reduction in hospital readmission for HF (Crowley 2017; Eurich 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver dysfunction, including cirrhosis, may be associated with a survival benefit in carefully selected patients (Brackett 2010; Crowley 2017; Zhang 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metformin accumulation and lactic acidosis increases with degree of renal impairment. Use is contraindicated in patients with eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>. Assess benefits/risks of metformin use in patients with eGFR 30 to 45 mL/minute/1.73 m<sup>2</sup>; if used, dosage reduction is recommended (ADA [Lipska 2011]; Inzucchi 2014; McCulloch 2017). Some experts recommend avoiding initiation of metformin in these patients (AACE [Garber 2017]; ADA [Lipska 2011]; Inzucchi 2014), while others suggest initiation may be reasonable in the absence of active kidney disease and/or conditions that predispose to hypoperfusion and hypoxemia (McCulloch 2017). Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; risk of metformin associated lactic acidosis increases with age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablet: Insoluble tablet shell (Glumetza 1,000 mg tablet) may remain intact and be visible in the stool. Other extended-released tablets (Fortamet, Glucophage XR, Glumetza 500 mg) may appear in the stool as a soft mass resembling the tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&bull; </i>Appropriate use<i>: </i>Not indicated for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis (DKA).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m<sup>2</sup>; or with a history of hepatic disease, alcoholism, or heart failure; or in patients who will receive intra-arterial iodinated contrast. Reevaluate eGFR 48 hours after imaging procedure; restart if renal function is stable. Alternatively, the American College of Radiology (ACR) guidelines recommend that metformin may be used prior to or following administration of iodinated contrast media in patients with no evidence of acute kidney injury (AKI) and with an eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>; ACR guidelines recommend temporary discontinuation of metformin in patients with known AKI or severe chronic kidney disease ([stage IV or V [ie, eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>]) or who are undergoing arterial catheter studies (ACR 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical procedures: Metformin should be withheld the day of surgery (all other oral hypoglycemic agents should be withheld the morning of surgery or procedure) (ADA 2018e). Restart only after normal oral intake resumed and normal renal function is verified.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27259218\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin B<sub>12</sub> serum concentrations may decrease to suboptimal levels with metformin use; although clinical manifestations do not usually appear, in very rare instances anemia has occurred; anemia is rapidly reversed with vitamin B<sub>12 </sub>supplementation or discontinuation of metformin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299680\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193826\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12589&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of MetFORMIN. Specifically, alcohol may potentiate the risk of lactic acidosis<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dalfampridine: MetFORMIN may increase the serum concentration of Dalfampridine. Dalfampridine may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: May increase the serum concentration of MetFORMIN. Management: Limit the daily metformin dose to 1,000 mg when used together with dolutegravir.  Metformin dose adjustments may also be needed upon discontinuation of dolutegravir.  Monitor patient response to metformin closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Management advice varies. Refer to the full drug interaction monograph content for details.<b> Exceptions: </b>Diatrizoate Meglumine; Diatrizoate Sodium; Ethiodized Oil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ondansetron: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patiromer: May decrease the serum concentration of MetFORMIN. Management: Administer metformin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of MetFORMIN. Management: Limit the metformin dose to a maximum of 1700 mg/day when used together with ranolazine 1000 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May enhance the adverse/toxic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trospium: MetFORMIN may decrease the serum concentration of Trospium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vandetanib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May diminish the therapeutic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193854\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases the extent and slightly delays the absorption. Management: Administer with a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193828\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193843\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Metformin has been found to cross the placenta in concentrations which may be comparable to those found in the maternal plasma. Pharmacokinetic studies suggest that clearance of metformin may increase during pregnancy and dosing may need adjusted in some women when used during the third trimester (Charles 2006; de Oliveira Baraldi 2011; Eyal 2010; Gardiner 2003; Hughes 2006; Vanky 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">An increased risk of birth defects or adverse fetal/neonatal outcomes has not been observed following maternal use of metformin for GDM or type 2 diabetes when glycemic control is maintained (Balani 2009; Coetzee 1979; Coetzee 1984; Ekpebegh 2007; Niromanesh 2012; Rowan 2008; Rowan 2010; Tertti 2008). However, available guidelines note that long-term safety data is not available (ACOG 190 2018; ADA 2018c)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013). Agents other than metformin are currently recommended to treat diabetes in pregnant women (ADA 2018c). However metformin may be used as an alternative agent in some patients requiring therapy for gestational diabetes mellitus (ACOG 190 2018).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060244\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood glucose (frequency based on patient-specific factors), hemoglobin A<sub>1c</sub> (every 3 months; AAP [Copeland 2013]) and fructosamine, initial and periodic monitoring of hemoglobin, hematocrit, and red blood cell indices; renal function (baseline and annually); urine for glucose and ketones.  While megaloblastic anemia has been rarely seen with metformin, if suspected, vitamin B<sub>12</sub> deficiency should be excluded.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060247\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Diabetes Patients (ADA 2016): <b>Note:</b> Goals should be individualized based on individual needs/circumstances (eg, patients who experience severe hypoglycemia, patients with hypoglycemic unawareness); lower goals may be reasonable if they can be achieved without excessive hypoglycemia. <b>Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the &quot;peak.&quot;</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial glucose: 90 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime/overnight glucose: 90 to 150 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults, nonpregnant:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postprandial glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193820\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193839\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within days; maximum effects up to 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 654 &plusmn; 358 L; partitions into erythrocytes; concentrates in liver, kidney, and GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Negligible</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Not metabolized by the liver</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Absolute: Fasting: 50% to 60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Plasma: 4 to 9 hours; Blood ~17.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release: 2 to 3 hours; Extended release: 7 hours (range: 4 to 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (90% as unchanged drug; active secretion) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060254\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">In a significant trial, Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) results showed that metformin monotherapy is inadequate at maintaining durable glycemic control in the majority of pediatric patients 10 to 17 years; metformin combined with rosiglitazone was superior than metformin monotherapy and metformin along with intensive lifestyle changes was intermediate (AAP [Copeland 2013]; Narasimhan 2014; TODAY Study Group 2013). Pediatric patients may require early aggressive therapy that is not defined at present (AAP [Copeland 2013]).  Rosiglitazone therapy is associated with severe cardiovascular effects in adult patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193842\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (D-Care DM2 Combination)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (110): $1,489.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Riomet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (118 mL): $199.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Fortamet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $2,530.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $2,530.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Glucophage XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $120.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (100): $181.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Glumetza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $6,177.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (90): $12,023.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (MetFORMIN HCl ER (MOD) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $5,559.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (90): $10,820.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (MetFORMIN HCl ER (OSM) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $1,034.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $1,884.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (MetFORMIN HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $74.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (100): $119.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Glucophage Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $118.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">850 mg (100): $201.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (100): $244.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MetFORMIN HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $70.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">850 mg (100): $119.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (500): $721.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193846\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adecco (ID);</li>\n      <li>Ansures (MY, PH);</li>\n      <li>Bentic (PY);</li>\n      <li>Biguax (CO);</li>\n      <li>Dabex (MX);</li>\n      <li>Dainipron (HK);</li>\n      <li>Deson (TH);</li>\n      <li>DH-Metglu 850 (VN);</li>\n      <li>DH-Metglu XR 1000 (VN);</li>\n      <li>Diabemet (MY);</li>\n      <li>Diabetase (DE);</li>\n      <li>Diabetmin (HK, MY, SG);</li>\n      <li>Diabetmin Retard (HK);</li>\n      <li>Diabetmin XR (SG);</li>\n      <li>Diabetol (PY);</li>\n      <li>Diabex (AU, KR);</li>\n      <li>Diabex XR (AU);</li>\n      <li>Diafat (PH);</li>\n      <li>Diaformin (BR, HK, TW, UA);</li>\n      <li>Diaformin XR (AU, ID);</li>\n      <li>Diaformina (UY);</li>\n      <li>Diaformina LP (UY);</li>\n      <li>Dialon (AE, BH, KW, LB, QA, SA);</li>\n      <li>Diamet (JO);</li>\n      <li>Dianben (ES);</li>\n      <li>Diaslim (TH);</li>\n      <li>Diformin (FI);</li>\n      <li>Diformin Retard (FI);</li>\n      <li>Dimefor (CO, MX, PE);</li>\n      <li>Dimet (ET);</li>\n      <li>Emnorm (NZ);</li>\n      <li>Euform Retard (PH);</li>\n      <li>Fordica 500 XR (ID);</li>\n      <li>Formet (AU, JO, MY);</li>\n      <li>Formin (BD, IN);</li>\n      <li>Formit (AE, BH, KW, QA, SA);</li>\n      <li>Fornidd (PH);</li>\n      <li>Glafornil (CL);</li>\n      <li>Glibudon (TW);</li>\n      <li>Glicenex (EC);</li>\n      <li>Glicophage (RO);</li>\n      <li>Glifage (BR);</li>\n      <li>Gliformin (CO);</li>\n      <li>Glisulin XR (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gluciophage XR (VN);</li>\n      <li>Gluco (TH);</li>\n      <li>Glucodown (KR);</li>\n      <li>Glucofage (EC, VE);</li>\n      <li>Glucofor (ID);</li>\n      <li>Glucoform (PH);</li>\n      <li>Glucogen (KR);</li>\n      <li>Glucoles (TH);</li>\n      <li>Glucomet (AU, ET, SG);</li>\n      <li>Glucomin (IL);</li>\n      <li>Glucomine (TW);</li>\n      <li>Glucon (MY);</li>\n      <li>Glucophage (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CN, CY, CZ, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, OM, PE, PH, PK, PT, QA, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Glucophage Forte (CZ, NL, PH);</li>\n      <li>Glucophage Retard (EG, IL, QA);</li>\n      <li>Glucophage SR (GB, IE);</li>\n      <li>Glucophage XR (AE, BB, CN, HK, KW, LB, MY);</li>\n      <li>Glucophage-Mite (DE);</li>\n      <li>Glucotika (ID);</li>\n      <li>Glucotin (PH);</li>\n      <li>Gludepatic (ID);</li>\n      <li>Glufor (ID, IL);</li>\n      <li>Glumet (MY, PH);</li>\n      <li>Glumet DC (MY);</li>\n      <li>Glumet Forte (HK);</li>\n      <li>Glumet XR (PH);</li>\n      <li>Glumin (ID);</li>\n      <li>Glumin XR (ID);</li>\n      <li>Glunor (PE);</li>\n      <li>Glupa (KR);</li>\n      <li>Glustress (TH);</li>\n      <li>Glutamet (ET);</li>\n      <li>Glyciphage (IN);</li>\n      <li>Glycomet (SG);</li>\n      <li>Glycomin (KR);</li>\n      <li>Glyformin (TW);</li>\n      <li>Glymet (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Guamet (HK);</li>\n      <li>Heskopaq (ID);</li>\n      <li>Humamet (PH);</li>\n      <li>Humamet XR (PH);</li>\n      <li>I-Max (PH);</li>\n      <li>Indform (VN);</li>\n      <li>Insufor (UA);</li>\n      <li>Insumed (PH);</li>\n      <li>Islotin (AR);</li>\n      <li>Lucomet (IE);</li>\n      <li>Maformin (TH);</li>\n      <li>Medfort (PE);</li>\n      <li>Mefarmil (UA);</li>\n      <li>Meglucon (DE);</li>\n      <li>Melbin (HK, JP);</li>\n      <li>Merckformin (HU);</li>\n      <li>Mescorit (DE);</li>\n      <li>Metamin (UA);</li>\n      <li>Metchek (NZ);</li>\n      <li>Metdia (VN);</li>\n      <li>Metex XR (AU);</li>\n      <li>Metfar (BD);</li>\n      <li>Metfin (ZW);</li>\n      <li>Metfogamma (DE, LV);</li>\n      <li>Metfor (AE, BH, QA);</li>\n      <li>Metfor XR (PH);</li>\n      <li>Metforal (CR, DO, EC, GT, HN, IT, LT, LV, NI, PA, SG, SV);</li>\n      <li>Metform (BD);</li>\n      <li>Metformax (LU);</li>\n      <li>Metgluco (JP);</li>\n      <li>Metgreen-SR (KR);</li>\n      <li>Metophage (IE);</li>\n      <li>Metta SR (ZW);</li>\n      <li>Miformin (TH);</li>\n      <li>Neoform (PH);</li>\n      <li>Normax (PH);</li>\n      <li>Orabet (AT, DK, GB, IE);</li>\n      <li>Predial (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Quexel (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Risidon (PT);</li>\n      <li>Siamformet (TH);</li>\n      <li>Siofor (BG, DE, PL, SI, SK);</li>\n      <li>Stagid (PT);</li>\n      <li>Sukkarto SR (GB);</li>\n      <li>Thiabet (DE);</li>\n      <li>Walaphage (IN);</li>\n      <li>Xmet (ET);</li>\n      <li>Yaltormin (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Gynecology, &quot;ACOG Practice Bulletin No. 108: Polycystic Ovary Syndrome,&quot; <i>Obstet Gynecol</i>, 2009, 114(4):936-49.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23969827 /pubmed\" target=\"_blank\" id=\"23969827 \">23969827 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 9. http://www.acr.org/Quality-Safety/Resources/~/media/37D84428BF1D4E1B9A3A2918DA9E27A3.pdf. Published 2013. Accessed November 14, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 13. Management of Diabetes in Pregnancy. <i>Diabetes Care</i>. 2017c;40(Suppl 1):S114-S119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27979900/pubmed\" target=\"_blank\" id=\"27979900\">27979900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). Professional practice committee for the standards of medical care in Diabetes-2015. <i>Diabetes Care</i>. 2015 Jan;38(Supplement 1):S1-S89</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA), &quot;Standards of Medical Care in Diabetes-2013,&quot; <i>Diabetes Care</i>, 2013, (36 Suppl 1):S11-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23264422/pubmed\" target=\"_blank\" id=\"23264422\">23264422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). Standards of medical care in diabetes - 2014. <i>Diabetes Care.</i> 2014;37(1):S14-S74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23264422/pubmed\" target=\"_blank\" id=\"23264422\">23264422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). Standards of medical care in diabetes 2016. <i>Diabetes Care</i>. 2016;39(Suppl 1):S1-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24357209 /pubmed\" target=\"_blank\" id=\"24357209 \">24357209 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). Type 2 diabetes in children and adolescents. <i>Diabetes Care</i>. 2000. 23(3):381-389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/10868870 /pubmed\" target=\"_blank\" id=\"10868870 \">10868870 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Society for Reproductive Medicine (ASRM) Practice Committee. Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. <i>Fertil Steril</i>. 2008;90(5 Suppl):S69-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/19007650/pubmed\" target=\"_blank\" id=\"19007650\">19007650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balani J, Hyer SL, Rodin DA, et al, &quot;Pregnancy Outcomes in Women With Gestational Diabetes Treated With Metformin or Insulin: A Case-Control Study,&quot; <i>Diabet Med</i>, 2009, 26(8):798-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/19709150/pubmed\" target=\"_blank\" id=\"19709150\">19709150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briggs GG, Ambrose PJ, Nageotte MP, et al, &quot;Excretion of Metformin Into Breast Milk and the Effect on Nursing Infants,&quot; <i>Obstet Gynecol</i>, 2005, 105(6):1437-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15932841/pubmed\" target=\"_blank\" id=\"15932841\">15932841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charles B, Norris R, Xiao X, et al, &quot;Population Pharmacokinetics of Metformin in Late Pregnancy,&quot; <i>Ther Drug Monit</i>, 2006, 28(1):67-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16418696/pubmed\" target=\"_blank\" id=\"16418696\">16418696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coetzee EJ and Jackson WP, &quot;Metformin in Management of Pregnant Insulin-Independent Diabetics,&quot; <i>Diabetologia</i>, 1979, 16(4):241-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/428695/pubmed\" target=\"_blank\" id=\"428695\">428695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coetzee EJ and Jackson WP, &quot;Oral Hypoglycaemics in the First Trimester and Fetal Outcome,&quot; <i>S Afr Med J</i>, 1984, 65(16):635-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/6369573/pubmed\" target=\"_blank\" id=\"6369573\">6369573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23359574 /pubmed\" target=\"_blank\" id=\"23359574 \">23359574 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo; <i>Ann Intern Med</i>, 1999, 131(4):281-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/10454950 /pubmed\" target=\"_blank\" id=\"10454950 \">10454950 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Oliveira Baraldi C, Lanchote VL, de Jesus Antunes N, et al, &quot;Metformin Pharmacokinetics in Nondiabetic Pregnant Women With Polycystic Ovary Syndrome,&quot; <i>Eur J Clin Pharmacol</i>, 2011, 67(10):1027-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21538144/pubmed\" target=\"_blank\" id=\"21538144\">21538144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ekpebegh CO, Coetzee EJ, van der Merwe L, et al, &quot;A 10-Year Retrospective Analysis of Pregnancy Outcome in Pregestational Type 2 Diabetes: Comparison of Insulin and Oral Glucose-Lowering Agents,&quot; <i>Diabet Med</i>, 2007, 24(3):253-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17305787/pubmed\" target=\"_blank\" id=\"17305787\">17305787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyal S, Easterling TR, Carr D, et al, &quot;Pharmacokinetics of Metformin During Pregnancy,&quot; <i>Drug Metab Dispos</i>, 2010, 38(5):833-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/20118196/pubmed\" target=\"_blank\" id=\"20118196\">20118196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fauser BC, Tarlatzis BC, Rebar RW, et al, &quot;Consensus on Women's Health Aspects of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,&quot; <i>Fertil Steril</i>, 2012, 97(1):28-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22153789 /pubmed\" target=\"_blank\" id=\"22153789 \">22153789 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortamet (metformin) [prescribing information]. Ft. Lauderdale, FL: First Horizon; July 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ, Kirkpatrick CM, Begg EJ, et al, &quot;Transfer of Metformin Into Human Milk,&quot; <i>Clin Pharmacol Ther</i>, 2003, 73(1):71-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/12545145/pubmed\" target=\"_blank\" id=\"12545145\">12545145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; August 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glucophage XR (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; August 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glueck CJ, Goldenberg N, Pranikoff J, et al, &quot;Effects of Metformin-Diet Intervention Before and Throughout Pregnancy on Obstetric and Neonatal Outcomes in Patients With Polycystic Ovary Syndrome,&quot; <i>Curr Med Res Opin</i>, 2013, 29(1):55-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23205605/pubmed\" target=\"_blank\" id=\"23205605\">23205605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glumetza (metformin) [prescribing information]. Menlo Park, CA: Depomed; December 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hale TW, Kristensen JH, Hackett LP, et al, &quot;Transfer of Metformin Into Human Milk,&quot; <i>Diabetologia</i>, 2002, 45(11):1509-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/12436333/pubmed\" target=\"_blank\" id=\"12436333\">12436333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RC and Rowan JA, &ldquo;Pregnancy in Women With Type 2 Diabetes: Who Takes Metformin and What Is the Outcome?&rdquo; <i>Diabet Med</i>, 2006, 23(3):318-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16492217/pubmed\" target=\"_blank\" id=\"16492217\">16492217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones K, Arlanian S, McVie R, et al, &ldquo;Metformin Improves Glycemic Control in Children With Type 2 Diabetes,&rdquo; <i>Diabetes</i>, 2000, 49(Suppl 1):A75.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly AS, Barlow SE, Rao G, et al. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(15):1689-1712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24016455 /pubmed\" target=\"_blank\" id=\"24016455 \">24016455 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. <i>J Clin Endocrinol Metab</i>. 2013;98(1):322-329.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23175691 /pubmed\" target=\"_blank\" id=\"23175691 \">23175691 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al, &quot;Managing Preexisting Diabetes for Pregnancy: Summary of Evidence and Consensus Recommendations for Care,&quot; <i>Diabetes Care</i>, 2008, 31(5):1060-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431-1437.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21617112/pubmed\" target=\"_blank\" id=\"21617112\">21617112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matson KL, Fallon RM. Treatment of obesity in children and adolescents. <i>J Pediatr Pharmacol Ther</i>. 2012;17(1):45-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23185143 /pubmed\" target=\"_blank\" id=\"23185143 \">23185143 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. <i>JAMA Pediatr</i>. 2014;168(2):178-184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24343296 /pubmed\" target=\"_blank\" id=\"24343296 \">24343296 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):S251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Chronic Conditions (UK). Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians (UK). National Institute for Health and Clinical Excellence: Guidance. 2008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21678628 /pubmed\" target=\"_blank\" id=\"21678628 \">21678628 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Narasimhan S, Weinstock RS. Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. <i>Mayo Clin Proc</i>. 2014;89(6):806-816.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24702733 /pubmed\" target=\"_blank\" id=\"24702733 \">24702733 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niromanesh S, Alavi A, Sharbaf FR, et al, &quot;Metformin Compared With Insulin in the Management of Gestational Diabetes Mellitus: A Randomized Clinical Trial,&quot; <i>Diabetes Res Clin Pract</i>, 2012, 98(3):422-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23068960/pubmed\" target=\"_blank\" id=\"23068960\">23068960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riomet [prescribing information]. Jacksonville, FL: Ranbaxy; July 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowan JA, Gao W, Hague WM, et al, &quot;Glycemia and Its Relationship to Outcomes in the Metformin in Gestational Diabetes Trial,&quot; <i>Diabetes Care</i>, 2010, 33(1):9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/19846793/pubmed\" target=\"_blank\" id=\"19846793\">19846793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowan JA, Hague WM, Gao W, et al, &ldquo;Metformin Versus Insulin for the Treatment of Gestational Diabetes,&rdquo; <i>N Engl J Med</i>, 2008, 358(19):2003-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18463376/pubmed\" target=\"_blank\" id=\"18463376\">18463376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw JS, Wilmont RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med. 2007;24(10):1160-1163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17672860/pubmed\" target=\"_blank\" id=\"17672860\">17672860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tertti K, Ekblad U, Vahlberg T, et al, &quot;Comparison of Metformin and Insulin in the Treatment of Gestational Diabetes: A Retrospective, Case-Control Study,&quot; <i>Rev Diabet Stud</i>, 2008, 5(2):95-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18795211/pubmed\" target=\"_blank\" id=\"18795211\">18795211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TODAY Study Group. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. <i>Diabetes Care</i>. 2013;36(6):1765-1771.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23704676 /pubmed\" target=\"_blank\" id=\"23704676 \">23704676 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanky E, Zahlsen K, Spigset O, et al, &quot;Placental Passage of Metformin in Women With Polycystic Ovary Syndrome,&quot; <i>Fertil Steril</i>, 2005, 83(5):1575-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15866611/pubmed\" target=\"_blank\" id=\"15866611\">15866611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson DM, Abrams SH, Aye T, et al. Glaser Pediatric Research Network Obesity Study Group. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. <i>Arch Pediatr Adolesc Med</i>. 2010;164(2):116-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/20124139 /pubmed\" target=\"_blank\" id=\"20124139 \">20124139 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. <i>Diabetes</i>. 2011;60(2):477-485.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21228310 /pubmed\" target=\"_blank\" id=\"21228310 \">21228310 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeitler P, Fu J, Tandon N, et al. Type 2 diabetes in the child and adolescent. <i>Pediatr Diabetes</i>. 2014;15(Suppl 20):26-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/25182306 /pubmed\" target=\"_blank\" id=\"25182306 \">25182306 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12589 Version 272.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709034\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193858\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193859\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060245\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060238\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193832\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F193817\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25484130\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060249\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F193853\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060248\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F193915\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193913\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193840\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193821\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27259218\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299680\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193826\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F193854\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193828\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F193843\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060244\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1060247\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193820\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F193839\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1060254\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F193842\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193846\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12589|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">Metformin: Drug information</a></li><li><a href=\"topic.htm?path=metformin-patient-drug-information\" class=\"drug drug_patient\">Metformin: Patient drug information</a></li></ul></div></div>","javascript":null}